Shares of Greenwich LifeSciences, Inc. [NASDAQ: GLSI] surged more than 12% during the pre-market trading session of Friday after the firm has reported the positive results of the Phase IIB clinical study. Greenwich has disclosed that the summary published at AACR demonstrates the GP2 final 5-year immune response data from the Phase IIb clinical study.
The powerful immune response data has backed the earlier disclosed experimental results of 0% metastatic breast cancer relapses over 5 years of follow-up. Furthermore, AACR released the Phase IIb final 5-year immune response data summary on Friday, April 9th. It is also intending to release the related poster on Saturday, April 10th.
The poster demonstrations will contain the final 5-year safety data of the GP2 Phase IIb experimental study and an initiation to the temporary assessment and experimental strategy of the scheduled Phase III experimental study.
Greenwich’s main aim is to develop treatment and fulfill the unmet medical needs of the sufferers. It has been reported that one in eight women in the US experience breast cancer in her life. It includes nearly 266,000 new breast cancer sufferers and 3.1 million breast cancer fighters in 2018.
The firm has disclosed that statistically meaningful peak immunity was achieved after 6 months of GP2 therapy as assessed in both a GP2 specific CD8 T cell dimer binding assay and a rescheduled-type-hypersensitivity (DTH) skin test.